A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)

NCT02531373 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

338

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Infections

Interventions

BIOLOGICAL: V114 Medium Dose
BIOLOGICAL: V114 High Dose
BIOLOGICAL: V114 Medium Dose with Alternative Carrier Protein
BIOLOGICAL: V114 High Dose with Alternative Carrier Protein
BIOLOGICAL: Prevnar 13™

Sponsor

Merck Sharp & Dohme LLC